EXAS logo

Exact Sciences (EXAS) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

01 February 2001

Indexes:

Not included

Description:

Exact Sciences Corporation is one of the leading companies in the development of tests for the diagnosis of oncological diseases. It is the developer of several of the most effective test brands in the field of cancer screening and diagnosis - including Cologuard (diagnosis of colorectal cancer) and Oncotype DX (diagnosis of breast, prostate, and colon cancer). Currently, they are working on creating additional tests for other types of cancer. The company was founded in 1995. The headquarters are located in Madison, Wisconsin. Exact has agreements for cooperation and licensing with the Mayo Clinic Foundation for Medical Education and Research, licensing agreements with Hologic, Biocartis, Epic Sciences, and others.

Events Calendar

Earnings

Next earnings date:

Feb 21, 2025

Recent quarterly earnings:

Nov 05, 2024

Recent annual earnings:

Feb 21, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

13 Dec '24 B of A Securities
Buy
26 Nov '24 TD Cowen
Buy
26 Nov '24 BTIG
Buy
11 Nov '24 Piper Sandler
Overweight
06 Nov '24 TD Cowen
Buy
06 Nov '24 Stifel
Buy
06 Nov '24 Jefferies
Buy
06 Nov '24 Goldman Sachs
Buy
06 Nov '24 Evercore ISI Group
Outperform
06 Nov '24 Craig-Hallum
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Exact Sciences Corporation (EXAS) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Exact Sciences Corporation (EXAS) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Exact Sciences Corporation (EXAS) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
EXAS
seekingalpha.com04 December 2024

Exact Sciences Corporation (NASDAQ:EXAS) will participate in the Annual Evercore ISI HealthCONx Healthcare Conference on December 4, 2024, at 7:30 AM ET. The company will be represented by CEO Kevin Conroy and CFO Aaron Bloomer. Vijay Kumar from Evercore will also be part of the conference call.

Exact Sciences Corporation (EXAS) Citi's 2024 Global Healthcare Conference (Transcript)
Exact Sciences Corporation (EXAS) Citi's 2024 Global Healthcare Conference (Transcript)
Exact Sciences Corporation (EXAS) Citi's 2024 Global Healthcare Conference (Transcript)
EXAS
seekingalpha.com03 December 2024

Exact Sciences Corporation (NASDAQ:EXAS) will be participating in Citi's 2024 Global Healthcare Conference on December 3, 2024, at 8:45 AM ET. The company will be represented by Kevin Conroy, the Chairman and CEO, and Aaron Bloomer, the EVP of Finance. Patrick Donnelly from Citi will also be part of the conference call.

Exact Sciences and Lil Jon Partner on “Get Low #2” Campaign to Encourage Colon Cancer Screening
Exact Sciences and Lil Jon Partner on “Get Low #2” Campaign to Encourage Colon Cancer Screening
Exact Sciences and Lil Jon Partner on “Get Low #2” Campaign to Encourage Colon Cancer Screening
EXAS
businesswire.com02 December 2024

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp., a top provider of cancer screening and diagnostic tests, has partnered with Grammy award-winning artist Lil Jon for the “Get Low #2” campaign aimed at boosting colon cancer screenings, which is the second leading cause of cancer deaths in the U.S. This collaboration also promotes the Cologuard® test as a useful, non-invasive option to enhance screening rates for adults aged 45 and older who qualify. The stool-based Cologuard test addresses various barriers to screening.

Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)
Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)
Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)
EXAS
benzinga.com26 November 2024

Editor's note: The title of this article has been changed to fix a mistake about the day of the week mentioned.

Exact Sciences to Participate in December Investor Conferences
Exact Sciences to Participate in December Investor Conferences
Exact Sciences to Participate in December Investor Conferences
EXAS
businesswire.com26 November 2024

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a top provider of cancer screening and diagnostic tests, has announced that its management will take part in upcoming conferences and invites investors to join via webcast. They will be at the Citi Global Healthcare Conference in Miami for a fireside chat on Tuesday, December 3, 2024, at 8:45 a.m. ET, and at the Evercore HealthCONx Conference in Miami for another fireside chat on Wednesday, December 4, 2024, at 7:30 a.m. ET. The webcasts will be available for access.

Why Is Exact Sciences Stock Trading Higher On Monday?
Why Is Exact Sciences Stock Trading Higher On Monday?
Why Is Exact Sciences Stock Trading Higher On Monday?
EXAS
benzinga.com26 November 2024

On Monday, the Centers for Medicare & Medicaid Services released the final payment decisions for the Clinical Laboratory Fee Schedule for 2025.

Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
EXAS
businesswire.com25 November 2024

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a top provider of cancer screening and diagnostic tests, will showcase 10 abstracts highlighting its Precision Oncology portfolio at the 2024 San Antonio Breast Cancer Symposium® (SABCS®) from December 10-13 in San Antonio, Texas. “Exact Sciences is dedicated to enhancing breast cancer care by offering valuable insights that aid in making informed treatment choices and achieving optimal results.”

Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript)
Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript)
Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript)
EXAS
seekingalpha.com19 November 2024

Exact Sciences Corporation (NASDAQ:EXAS) will be participating in the Jefferies London Healthcare Conference on November 19, 2024, at 6:00 AM ET. The company will be represented by Kevin Conroy, the Chairman and CEO, and Aaron Bloomer, the Chief Financial Officer. During the conference, Tycho Peterson from Jefferies will ask Kevin about a recent acquisition.

EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test
EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test
EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test
EXAS
zacks.com18 November 2024

Exact Sciences has shared new encouraging information that supports the creation of an MCED test.

Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
EXAS
businesswire.com13 November 2024

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a top company in cancer screening and diagnostic tests, will share three abstracts that showcase important progress in creating a multi-cancer early detection (MCED) test. A study on a new multi-biomarker method demonstrated better sensitivity for detecting early-stage and overall cancer. Furthermore, new modeling data suggests that including MCED testing in recommended screenings could be beneficial.

FAQ

  • What is the primary business of Exact Sciences?
  • What is the ticker symbol for Exact Sciences?
  • Does Exact Sciences pay dividends?
  • What sector is Exact Sciences in?
  • What industry is Exact Sciences in?
  • What country is Exact Sciences based in?
  • When did Exact Sciences go public?
  • Is Exact Sciences in the S&P 500?
  • Is Exact Sciences in the NASDAQ 100?
  • Is Exact Sciences in the Dow Jones?
  • When was Exact Sciences's last earnings report?
  • When does Exact Sciences report earnings?
  • Should I buy Exact Sciences stock now?

What is the primary business of Exact Sciences?

Exact Sciences Corporation is one of the leading companies in the development of tests for the diagnosis of oncological diseases. It is the developer of several of the most effective test brands in the field of cancer screening and diagnosis - including Cologuard (diagnosis of colorectal cancer) and Oncotype DX (diagnosis of breast, prostate, and colon cancer). Currently, they are working on creating additional tests for other types of cancer. The company was founded in 1995. The headquarters are located in Madison, Wisconsin. Exact has agreements for cooperation and licensing with the Mayo Clinic Foundation for Medical Education and Research, licensing agreements with Hologic, Biocartis, Epic Sciences, and others.

What is the ticker symbol for Exact Sciences?

The ticker symbol for Exact Sciences is NASDAQ:EXAS

Does Exact Sciences pay dividends?

No, Exact Sciences does not pay dividends

What sector is Exact Sciences in?

Exact Sciences is in the Healthcare sector

What industry is Exact Sciences in?

Exact Sciences is in the Diagnostics & Research industry

What country is Exact Sciences based in?

Exact Sciences is headquartered in United States

When did Exact Sciences go public?

Exact Sciences's initial public offering (IPO) was on 01 February 2001

Is Exact Sciences in the S&P 500?

No, Exact Sciences is not included in the S&P 500 index

Is Exact Sciences in the NASDAQ 100?

No, Exact Sciences is not included in the NASDAQ 100 index

Is Exact Sciences in the Dow Jones?

No, Exact Sciences is not included in the Dow Jones index

When was Exact Sciences's last earnings report?

Exact Sciences's most recent earnings report was on 5 November 2024

When does Exact Sciences report earnings?

The next expected earnings date for Exact Sciences is 21 February 2025

Should I buy Exact Sciences stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions